Tower Research Capital (TRC)’s NewAmsterdam Pharma NAMS Stock Holding History

Tower Research Capital (TRC)’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$38.3K	Buy	1,198 +255	+27%	+$8.31K	﹤0.01%	2975
2025 Q4	$33.1K	Sell	943 -2,029	-68%	-$73.8K	﹤0.01%	2734
2025 Q3	$84.5K	Buy	2,972 +2,424	+442%	+$58.1K	﹤0.01%	2135
2025 Q2	$9.92K	Sell	548 -164	-23%	-$2.99K	﹤0.01%	3974
2025 Q1	$14.6K	Sell	712 -585	-45%	-$13K	﹤0.01%	3282
2024 Q4	$33.3K	Sell	1,297 -6,485	-83%	-$138K	﹤0.01%	2827
2024 Q3	$129K	Buy	+7,782	New	+$135K	﹤0.01%	2026
2023 Q1	–	Sell	-88	Closed	-$1K	–	6119
2022 Q4	$1K	Buy	+88	New	+$875	﹤0.01%	5633

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Tower Research Capital (TRC)'s NAMS Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its NewAmsterdam Pharma (NAMS) stake by 27% in Q1 2026, buying an estimated $8.31K and bringing the position to 1,198 shares worth $38.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2975.

Tower Research Capital (TRC) first reported a position in NAMS in Q4 2022 and has held it in 8 quarters since. The position peaked at $129K in Q3 2024. 170 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

Tower Research Capital (TRC) held 1,198 shares of NewAmsterdam Pharma worth $38.3K as of Q1 2026.
Tower Research Capital (TRC) bought 255 NewAmsterdam Pharma shares in Q1 2026, an estimated $8.31K.
NewAmsterdam Pharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2975 holding.
Tower Research Capital (TRC) first reported a position in NewAmsterdam Pharma in Q4 2022 and has held it in 8 quarters since.
Tower Research Capital (TRC)'s NewAmsterdam Pharma position peaked at $129K in Q3 2024.
170 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.